Small molecule compounds as JAK kinase inhibitors and their uses
Small molecule compounds targeting JAK1/TYK2 kinases provide effective treatment for autoimmune diseases and inflammatory skin diseases by inhibiting JAK kinases with high specificity and low systemic side effects.
Patent Information
- Application Number
- JP2023521673
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-10-09
- Filing Date
- 2021-09-24
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2041-09-24
AI Technical Summary
Current treatments for autoimmune diseases and inflammatory skin diseases lack effective, targeted inhibitors of JAK kinases that can selectively inhibit JAK1 and/or TYK2 without causing systemic side effects, particularly for external use.
Development of small molecule compounds that act as JAK1/TYK2 dual inhibitors and TYK2-specific inhibitors, designed to target specific JAK kinases, with IC50 values less than 200 nM, to inhibit JAK kinase activity and suppress inflammation.
The compounds demonstrate potent inhibitory effects on JAK kinases, offering therapeutic benefits for autoimmune diseases and inflammatory skin diseases with reduced systemic side effects.
Smart Images

Figure 0007587886000001 
Figure 0007587886000002 
Figure 0007587886000003
Abstract
Description
[Technical field]
[0001] [CROSS REFERENCE TO THIS APPLICATION] This invention claims priority to a patent application with application number CN202011072703.7, filed on October 9, 2020, and entitled "Small molecule compounds as JAK kinase inhibitors and their uses."
[0002] [Technical field] The present invention is in the field of small molecule compounds, and in particular relates to small molecule compounds that are used to prevent, treat or alleviate autoimmune diseases such as rheumatoid arthritis, ulcerative colitis and systemic lupus erythematosus, or related inflammatory skin diseases such as psoriasis, eczema, vitiligo and alopecia areata. [Background technology]
[0003] JAK (Janus Kinase) is a family of intracellular non-receptor tyrosine kinases, including four members: JAK1, JAK2, JAK3, and Tyk2. The JAK-STAT (Signal Transducer and Activator of Transcription proteins) signal transduction pathway is the main intracellular transduction pathway of signals triggered by the combination of inflammatory cytokines and receptors. A large body of evidence indicates that the JAK-STAT signal transduction pathway plays an essential driving role in the pathogenesis of many diseases, especially autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, inflammatory bowel disease, multiple sclerosis, Sjogren's syndrome, psoriasis, alopecia areata, and vitiligo, and allergic diseases such as asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and eczema. Therefore, the use of highly efficient small molecules to inhibit JAK kinase activity, particularly JAK1, TYK2 kinase activity, can block cytokine-mediated signaling pathways involved in inflammatory responses, thereby suppressing inflammation and effectively treating autoimmune and / or allergic inflammatory diseases.
[0004] In the development process of different inflammatory diseases, T cells differentiate in different directions by different inflammatory inducers such as virus or bacterial infection, generating T cell subsets such as Th1, Th2, and Th17, and these T cells produce various cytokines accordingly. For example, Th1 cells associated with acute inflammation caused by virus infection produce IFNγ and IL-2, Th2 cells associated with allergy produce IL-4, IL-5, and IL-13, and Th17 cells associated with autoimmunity produce IL-17, IL-12, IL-21, IL-22, and IL-23. These cytokines bind to receptors on the cell surface and transmit inflammatory signals through intracellular JAK to promote the pathological process of the disease. More importantly, many inflammatory diseases with unknown etiology have been revealed to have complex mechanisms involving multiple T cell subsets at different or the same stage. In other words, multiple JAK pathways are involved, presenting new requirements for the development of therapeutic drugs for inflammatory diseases targeting JAK.
[0005] Some studies have reported that JAK1 inhibitors can specifically inhibit Th2-based allergic inflammation, but there are few reports on the effective inhibition of JAK1 and / or TYK2 inhibitors. However, we believe that JAK1 / Tyk2 dual inhibitors and Tyk2 inhibitors have a broader clinical perspective, especially in inflammatory diseases caused by autoimmune abnormalities. In addition, since multiple JAKs may be involved in the pathogenesis of more inflammatory diseases, especially inflammatory skin diseases, it is very important to develop a strong single or dual inhibitor of JAK1 and Tyk2, especially in the topical treatment of skin diseases, a strong inhibitor can not only have excellent therapeutic effects, but also avoid the side effects caused by systematic dosing, but this requires strong activity inhibition at the same time. Summary of the Invention
[0006] The purpose of the present invention is to obtain a highly efficient JAK1 / Tyk2 dual inhibitor and Tyk2 specific inhibitor, and provide targeted treatment for different inflammatory diseases.For example, JAK1 / Tyk2 dual inhibitor may be suitable for SLE, vitiligo, IBD, eczema and other inflammatory diseases, and Tyk2 specific inhibitor is more suitable for the treatment of rheumatoid arthritis, psoriasis, alopecia areata, etc., and at the same time, it may overcome the hematopoietic inhibition and coagulation abnormality caused by the inhibition of JAK2.In addition, the JAK family inhibitor suitable for external use such as inflammatory skin disease can be selected according to the etiology and symptoms, and can be intervened in the disease to suppress the symptoms, thereby obtaining good therapeutic effect.
[0007] To achieve the above object, in one aspect, the present invention provides a small molecule compound represented by the following formula I, or a stereoisomer, geometric isomer, tautomer, hydrate, solvate, and pharma- ceutically acceptable salt or prodrug thereof: [ka] Where: R1 to R4 are each independently selected from C or N; and R is selected from cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl.
[0008] In one embodiment, a maximum of two of R1 to R4 are N.
[0009] In another embodiment, R has a structure represented by formula II: [ka] Where: R5 is selected from C or N; R6 is selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R7 is selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
[0010] In another embodiment, R6 and R7 are each independently selected from hydrogen, alkyl, or cycloalkyl.
[0011] In another embodiment, R has a structure represented by formula III: [ka] Where: R8 is selected from C or N; R9 is selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and R 10 is selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
[0012] In another embodiment, R and R 10 are each independently selected from hydrogen, alkyl, or cycloalkyl.
[0013] In another embodiment, the alkyl group is methyl, ethyl, propyl, or isopropyl, and the cycloalkyl group is cyclopropyl, cyclobutyl, or cyclopropylmethyl.
[0014] In another aspect, the present invention further provides the use of the small molecule compounds described above in the inhibition of JAK kinases.
[0015] In another aspect, the present invention further provides the use of the small molecule compound as described above in the preparation of a medicament for preventing or treating JAK-associated autoimmune diseases and immune-related inflammatory skin diseases.
[0016] In one embodiment, the autoimmune disease is selected from at least one of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, dermatomyositis, multiple sclerosis, type I diabetes, Sjogren's syndrome, and vasculitis.
[0017] In another embodiment, the immune-related inflammatory skin disease is selected from at least one of atopic dermatitis, eczema, alopecia areata, psoriasis, vitiligo, lichen planus, lichen nitidus, lichen sclerosus, panniculitis, acne, and hidradenitis suppurativa.
[0018] The functions and advantages of the present invention are as follows: The present invention has been carried out a purposeful and rational design of small molecule compounds according to the protein structure of JAK kinases, particularly that of Tyk2. The synthesized compounds were first tested for their biochemical activity against JAK kinases to establish the structure-activity relationship (SAR) by IC50 and to demonstrate an IC of less than 200 nM. 50 The potent inhibitors having the above structure were subjected to cytological testing to determine the selectivity of the compounds. Referring to the specific activity experimental data, it can be seen that the compounds involved in the present invention have good JAK kinase activity and cell biological activity inhibition ability. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] Hereinafter, specific embodiments of the present invention will be described in detail. It should be understood that the specific embodiments described herein are only used for the purpose of explaining and interpreting the present invention, and are not intended to limit the present invention.
[0020] It should be understood that the endpoints of the ranges and any values disclosed herein are not limited to the exact ranges or values, and that these ranges or values include values approaching these ranges or values. In the case of numerical ranges, it is possible to combine the endpoints of each range, the endpoints of each range and the individual point values, and the individual point values with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.
[0021] Before describing the invention in detail, it should be understood that the terms used herein are for describing particular embodiments and are not intended to limit the scope of the invention, which is defined solely by the appended claims. In order to provide a more complete understanding of the invention described herein, the following terms are used and are defined as follows: Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0022] In one aspect, the present invention provides a small molecule compound that is represented by Formula I: [ka] Where: R1 to R4 are each independently selected from C or N; R is selected from cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl.
[0023] That is, R1, R2, R3, and R4 may each be independently selected from C or N. In a preferred embodiment, a maximum of two (i.e., 0, 1, or 2) of R1 to R4 may be N. In another preferred embodiment, a maximum of one (i.e., 0 or 1) of R1 to R4 may be N. When a maximum of one (i.e., 0 or 1) of R1 to R4 is N, they form a benzene ring or a pyridine ring.
[0024] According to the present invention, in a preferred embodiment, R may have a structure represented by formula II shown below. [ka] Where: R5 may be selected from C or N; R6 may be selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; R7 may be selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
[0025] In a more preferred embodiment, R6 and R7 may each independently be selected from hydrogen, alkyl, or cycloalkyl, wherein the alkyl may be methyl, ethyl, propyl, or isopropyl, and the cycloalkyl may be cyclopropyl, cyclobutyl, or cyclopropylmethyl.
[0026] For example, in a specific embodiment, R5 is C, R6 is hydrogen, and R7 is ethyl, in which case R can have the structure shown below. [ka]
[0027] For example, in a specific embodiment, R5 is N, R6 is methyl, and R7 is methyl, in which case R can have the structure shown below. [ka]
[0028] For example, in a specific embodiment, R5 is C, R6 is methyl, and R7 is ethyl, in which case R can have the structure shown below. [ka]
[0029] For example, in a specific embodiment, R5 is N, R6 is methyl, and R7 is hydrogen, in which case R can have the structure shown below. TIFF0007587886000009.tif2841
[0030] According to another preferred embodiment of the present invention, R has a structure represented by formula III shown below. [ka] Where: R8 is selected from C or N; R9 is selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 10 is selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
[0031] In a more preferred embodiment, R and R 10 are each independently selected from hydrogen, alkyl, or cycloalkyl, and further, said alkyl groups are methyl, ethyl, propyl, or isopropyl, and said cycloalkyl groups are cyclopropyl, cyclobutyl, or cyclopropylmethyl.
[0032] For example, in a specific embodiment, R is N, R is hydrogen, and R 10is methyl. In this case, R can have the structure shown below. [ka]
[0033] According to the present invention, in another preferred embodiment, R can further have the structure shown below. [ka]
[0034] The term "pharmacologically acceptable" as used herein refers to a substance that does not affect the biological activity or properties of the compound according to the present invention and is relatively non-toxic. That is, the substance can be administered to an individual without causing adverse biological reactions or interacting undesirably with any of the components contained in the composition. In the present invention, "pharmacologically acceptable salts" include inorganic salts and organic salts, including but not limited to ammonium, lithium, sodium, potassium, cesium, calcium, magnesium, copper, aluminum, zinc, barium, or quaternary ammonium salts; inorganic salts include but are not limited to arginine, tert-butylamine, dimethylamine, diethanolamine, ethanolamine, ethylenediamine, imidazole, lysine, methylamine, pyridine, pyridine carboxylic acid ester, piperazine, triethylamine, triethanolamine, trimethylamine, or urea salts.
[0035] In another aspect, the present invention provides the use of the small molecule compounds as described above for inhibiting JAK kinases, particularly as dual JAK1 / Tyk2 inhibitors and Tyk2 specific inhibitors.
[0036] In another aspect, the present invention further provides a use of the small molecule compound in the preparation of a medicament for preventing or treating autoimmune diseases and immune-related inflammatory skin diseases, the pathogenesis of which has been shown to be related to dysregulation of JAK signaling.
[0037] The term "treatment" as used herein means that any administration of a therapeutic agent according to a treatment regimen results in the desired effect, i.e., partial or complete alleviation, amelioration, mitigation, inhibition, delay of onset, reduction in severity, and / or reduction in incidence of one or more symptoms or characteristics of a particular disease, disorder, and / or condition. In some embodiments, administration of a therapeutic agent according to a treatment regimen is associated with achieving a desired effect. Such treatment may be directed to subjects who do not exhibit the relevant disease, disorder, and / or condition, and / or subjects who exhibit only early signs of the disease, disorder, and / or condition. Alternatively or additionally, such treatment may be directed to subjects who exhibit one or more identified signs of the relevant disease, disorder, and / or condition. In some embodiments, treatment may be directed to subjects who have been diagnosed with the relevant disease, disorder, and / or condition. In some embodiments, treatment may be directed to subjects who have one or more predisposing factors statistically associated with an increased risk of developing the relevant disease, disorder, and / or condition.
[0038] According to the present invention, the medicaments prepared for the above uses may comprise an effective amount of a small molecule compound according to the present invention and a pharma- ceutically acceptable excipient, carrier or diluent.
[0039] As used herein, the term "effective amount," "therapeutically effective amount," or "pharmaceutical effective amount" refers to an amount of a therapeutic agent that confers a therapeutic effect on the treated subject, at a reasonable benefit / risk ratio appropriate for any drug treatment. Such therapeutic effect may be objective (i.e., measurable by some test or indication) or subjective (i.e., effect as reported or felt by the subject). In some embodiments, a "therapeutically effective amount" refers to an amount of a therapeutic agent or composition that effectively treats, ameliorates, or prevents (e.g., delays onset of) the associated disease or condition, and / or exhibits a detectable therapeutic or prophylactic effect, such as by ameliorating symptoms associated with the disease, preventing or delaying the onset of the disease, and / or reducing the severity or frequency of symptoms of the disease.
[0040] Those skilled in the art will recognize that the therapeutically effective amount of the small molecule compound administered will vary depending on the subject and the nature and severity of the disease, the subject's physical condition, the treatment regimen (e.g., with or without the use of a second therapeutic agent), and the selected route of administration. The appropriate dosage can be easily determined by those skilled in the art. Meanwhile, the optimal number and interval of individual administrations of the drug will be determined by the nature and extent of the pathology being treated, the form, route and site of administration, the age and pathology of the particular subject being treated, and the appropriate dosage will ultimately be determined by the physician. This dosage may be repeated multiple times as necessary, and if side effects occur, the amount and / or frequency of administration may be modified or reduced in accordance with normal clinical practice.
[0041] In the present invention, a "pharmaceutically acceptable excipient, carrier, or diluent" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier, etc., approved by the relevant government regulatory agency as acceptable for use in humans or veterinary animals.
[0042] According to the present invention, the pharmaceutical product prepared for the above-mentioned use may contain, as an active ingredient, a drug that can be used for the prevention or treatment of autoimmune diseases and immune-related inflammatory skin diseases, in addition to the small molecule compound according to the present invention. Examples of the drug include, but are not limited to, vitamin D derivatives, vitamin A derivatives, glucocorticoids, calcineurin inhibitors, nonsteroidal anti-inflammatory agents, etc. When the drug contains multiple active ingredients, each active ingredient may be administered simultaneously, sequentially, or separately, according to the doctor's judgment.
[0043] Meanwhile, the small molecule compounds of the present invention can be administered to patients by various routes, such as oral, transdermal, subcutaneous, intranasal, intravenous, intramuscular, intrathecal, regional or local (e.g., mucosal). The optimal route of administration in any given case is determined by the subject and the nature and severity of the disease, and the physical condition of the subject. In one embodiment, the small molecule compounds of the present invention can be administered intravenously. In another embodiment, the small molecule compounds of the present invention can be administered orally. Thus, depending on the different administration modes, the pharmaceutical preparations according to the present invention can be prepared in different dosage forms. For example, in one embodiment, the pharmaceutical preparations can be prepared as tablets, capsules, pills, granules, nebulizers, sprays, or injections.
[0044] Through research, it has been found that the small molecule compound of the present invention or the medicine prepared therewith can exert excellent effects when used for preventing or treating JAK-related autoimmune disease and immune-related inflammatory skin disease.Specifically, the autoimmune disease includes but is not limited to rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, dermatomyositis, multiple sclerosis, type I diabetes, Sjogren's syndrome, and vasculitis; the immune-related inflammatory skin disease includes but is not limited to atopic dermatitis, eczema, alopecia areata, psoriasis or vitiligo, lichen planus, lichen nitidus, lichen scleroatrophicus, panniculitis, acne, and hidradenitis suppurativa.
[0045] The effects of specific small molecule compounds of the present invention will be described in detail below through examples. EXAMPLES
[0046] <Example 1: General synthesis method of compound 1 (TDM-180972)> [ka] Step 1: Preparation of compound 1c (4-(2-chloropyrimidin-4-yl)aniline) Compound 1a (2 g, 9.129 mmol), compound 1b (1.36 g, 9.129 mmol), tetrakistriphenylphosphine palladium (527 g, 0.45 mmol), potassium carbonate (2.5 g, 18.258 mmol), dioxane (20 mL) and water (20 mL) were added to a three-neck flask, and the mixture was heated to 80°C and stirred for 45 minutes after replacing with nitrogen several times. After the reaction was completed, the reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 0-60%) to obtain the target compound (compound 1c, 394 mg, yield 21%) as a light yellow solid. LCMS [M+1] + = 206.
[0047] Step 2: Preparation of compound 1e ((S)-N-(4-(2-chloropyrimidin-4-yl)phenyl)-2,2-difluorocyclopropane-1-carboxamide) Compound 1c (300 mg, 1.459 mmol) and compound 1d (187 mg, 1.531 mmol) are added to a three-neck flask, the mixture is purged with nitrogen several times, and then pyridine (10 mL) and phosphorus oxychloride (335.6 mg, 2.189 mmol) are added at 0°C. The mixture is stirred at room temperature for 1 hour, concentrated under reduced pressure, the residue is extracted with ethyl acetate (30 mL * 3), the organic layers are combined, washed with water (50 mL * 3) and saturated saline (50 mL * 2), dried over sodium sulfate, the filtrate is concentrated under reduced pressure, and the residue is purified by silica gel chromatography (petroleum ether / ethyl acetate = 0 ~ 12%) to obtain the target compound (compound 1e, 327.7 mg, yield 72.5%) as a yellow solid. LCMS[M+H] + = 310.
[0048] Step 3: Preparation of compound 1 ((S)-4-((4-(4-(4-(2,2-difluorocyclopropane-1-carboxamido)phenyl)pyrimidin-2-yl)amino)-N-ethylbenzamide) Compound 1f (85 mg, 0.517 mmol) and p-toluenesulfonic acid monohydrate (98 mg, 0.517 mmol) are added to a solution of compound 1e (80 mg, 0.258 mmol) in n-butanol (8 ml). The resulting mixture is heated to 110° C. and stirred for 3 hours. After the reaction is complete, the mixture is concentrated under reduced pressure, and the residue is purified by preparative HPLC (formic acid) to obtain the target compound TDM-180972 (compound 1, 19.7 mg, yield 17.5%) as a yellow solid. LCMS[M+H] + = 438.2. 1 H NMR (400MHz, DMSO) δ 10.70(s, 1H), 9.91(s, 1H), 8.57(d, J = 5.3 Hz, 1H), 8.28(t, J = 5.5 Hz, 1H), 8.19(d, J = 8.8 Hz, 2H), 7.92(d, J = 8.9 Hz, 2H), 7.83(d, J = 8.9 Hz, 2H), 7.78(d, J = 8.8 Hz, 2H), 7.44(d, J = 5.3 Hz, 1H), 3.28(dt, J = 12.7, 6.4 Hz, 2H), 2.86(ddd, J = 13.6, 10.8, 8.0 Hz, 1H), 2.12 - 1.94(m, 2H), 1.13(t, J = 7.2 Hz, 3H).
[0049] <Example 2: General synthesis method of compound 2 (TDM-180974)> [ka] Step 1: Preparation of compound 2 ((S)-5-((4-(4-(4-(2,2-difluorocyclopropane-1-carboxamido)phenyl)pyrimidin-2-yl)amino)-3-methylpyridolin) Compound 2b (78 mg, 0.517 mmol) and p-toluenesulfonic acid monohydrate (98 mg, 0.517 mmol) are added to a solution of compound 2a (80 mg, 0.258 mmol) in n-butanol (8 mL), and the mixture is heated to 115° C. and stirred overnight. After the reaction is completed, the mixture is concentrated under reduced pressure, methanol is added to the residue, the solid is filtered, and the solid is purified by preparative HPLC (formic acid) to obtain the target compound TDM-180974 (compound 2, 18.9 mg, yield 10.6%) as a white solid. LCMS[M+H] + = 425.2. 1 H NMR (400MHz, DMSO) δ 10.73(s, 1H), 10.08(s, 1H), 8.89(d, J = 2.2Hz, 1H), 8.60(d, J = 5.3Hz, 1H), 8.23(d, J = 2.0Hz, 1H), 8.18(d, J = 8.8 Hz, 2H), 7.90(s, 1H), 7.79(d, J = 8.8 Hz, 2H), 7.49(d, J = 5.3 Hz, 1H), 7.26(s, 1H), 2.87(ddd, J = 13.6, 10.8, 8.1 Hz, 1H), 2.61(s, 3H), 2.10 - 1.96(m, 2H).
[0050] <Example 3: General synthesis method of compound 3 (TDM-180977)> [ka] Step 1: Preparation of compound 3b (4-amino-N-ethyl-2-methylbenzamide) To a solution of compound 3a (1.8 g, 11.91 mmol) in N,N-dimethylformamide (80 mL) is added 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (5.4 g, 14.289 mmol) and N,N-diisopropylethylamine (3.8 g, 29.775 mmol) and the mixture is stirred for 5 min, after which a solution of ethylamine in tetrahydrofuran (2 M) (9 mL, 18 mmol) is added and the mixture is stirred at room temperature overnight. The mixture is concentrated under reduced pressure to remove the solvent, water is added to the residue, and it is extracted with ethyl acetate (100 mL*3). The organic phases are combined, washed with water (150 mL*3) and saturated brine (150 mL), dried over sodium sulfate, and the filtrate is concentrated under reduced pressure and purified by silica gel chromatography (petroleum ether / ethyl acetate=0%~50%) to obtain the target compound (compound 3b, 1.32 g, yield 62.2%) as a yellow oil. LCMS [M+1] + = 179.
[0051] Step 2: Preparation of compound 3 ((S)-4-((4-(4-(4-(2,2-difluorocyclopropane-1-carboxamido)phenyl)pyrimidin-2-yl)amino)-N-ethyl-2-methylbenzamide) Compound 3b (92 mg, 0.517 mmol) and p-toluenesulfonic acid monohydrate (98 mg, 0.517 mmol) are added to a solution of compound 3c (80 mg, 0.258 mmol) in n-butanol (8 mL). The resulting mixture is heated to 110° C. and stirred for 3 hours. After the reaction is complete, the mixture is concentrated under reduced pressure, and the residue is purified by preparative HPLC (formic acid) to obtain the target compound TDM-180977 (compound 3, 19.4 mg, 13.3% yield) as a white solid. LCMS [M+H] + = 425.2. 1H NMR (400MHz, DMSO) δ 10.70(s, 1H), 9.72(s, 1H), 8.54(d, J = 5.3 Hz, 1H), 8.18(d, J = 8.8 Hz, 2H), 8.08(d, J = 5.6 Hz, 1H), 7.81 - 7.67(m, 4H), 7.40(d, J = 5.3 Hz, 1H), 7.32(d, J = 8.4 Hz, 1H), 3.28 - 3.17(m, 2H), 2.86(ddd, J = 13.6, 10.8, 8.1 Hz, 1H), 2.37(s, 3H), 2.14 - 1.93(m, 2H), 1.11(t, J = 7.2 Hz, 3H).
[0052] <Example 4: General synthesis method of compound 4 (TDM-180981)> [ka] Step 1: Preparation of compound 4 ((S)-5-((4-(4-(4-(2,2-difluorocyclopropane-1-carboxamido)phenyl)pyrimidin-2-yl)amino)-N,3-dimethylpyridolinamide) Compound 4 (white solid, 3.5 mg, 1.6% yield) was obtained by preparing in a similar manner to Example 3. 1 H NMR (400MHz, DMSO) δ 10.74(s, 1H), 10.06(s, 1H), 8.92(d, J = 2.2 Hz, 1H), 8.60(d, J = 5.3 Hz, 1H), 8.48(d, J = 4.8Hz, 1H), 8.22 - 8.18(m, 2H), 8.17(s, 1H), 7.78(d, J = 8.8Hz, 2H), 7.49(d, J = 5.3Hz, 1H), 2.87(ddd, J = 13.6, 10.8, 8.0 Hz, 1H), 2.78(d, J = 4.8 Hz, 3H), 2.61(s, 3H), 2.03(ddd, J = 18.1, 11.7, 6.0 Hz, 2H). LCMS[M+H] + = 439.2.
[0053] <Example 5: General synthesis method of compound 5 (TDM-180989)> [ka] Step 1: Preparation of compound 5c (2-(5-nitropyridin-2-yl)malonic acid 1-(tert-butyl) 3-methyl ester) At room temperature, potassium carbonate (17.435 g, 126.152 mmol) and compound 5b (13.185 g, 75.691 mmol) are added to a solution of compound 5a (10 g, 63.076 mmol) in N,N-dimethylformamide (100 mL). The mixture is purged with nitrogen several times. The mixture is heated to 100 °C and stirred overnight. After the reaction is completed, it is cooled to room temperature, saturated ammonium chloride solution (150 mL) is added and filtered, the filtrate is extracted with ethyl acetate (300 mL × 3), the organic layers are combined, washed with saturated saline (200 mL × 2), dried over sodium sulfate, the filtrate is concentrated under reduced pressure, and the residue is purified by silica gel chromatography (petroleum ether / ethyl acetate = 0% ~ 6%) to obtain the target compound (compound 5c, 7.286 g, yield 39%) as a yellow oil. LCMS [M-C4H9] + = 241.1.
[0054] Step 2: Preparation of compound 5d (1-(tert-butyl) 3-methyl-2-methyl-2-(5-nitropyridin-2-yl) malonate) At 0°C, cesium carbonate (15.4g, 47.252mmol) is added to a solution of compound 5c (7g, 23.626mmol) in N,N-dimethylformamide (150mL), the mixture is warmed to room temperature, stirred for 10 minutes, iodomethane (13.4g, 94.505mmol) is added, and the mixture is stirred at room temperature for 3 hours. After the reaction is completed, water (150mL) is added at 0°C, and the mixture is extracted with ethyl acetate (150mL x 3), the organic layers are combined, washed with saturated saline (250mL x 2), dried over sodium sulfate, the filtrate is concentrated under reduced pressure, and the residue is purified by silica gel chromatography (petroleum ether / ethyl acetate = 0% to 3%) to obtain the target compound (compound 5d, 6.026g, yield 82.2%) as a yellow oil. LCMS [M-C4H9] + = 255.1.
[0055] Step 3: Preparation of compound 5e (propyl 2-(5-nitropyridin-2-yl)propionate) To a solution of compound 5d (6 g, 19.366 mmol) in dichloromethane (150 mL), add trifluoroacetic acid (50 mL). Stir the mixture at room temperature for 3 hours. After the reaction is complete, concentrate the mixture under reduced pressure, and purify the residue by silica gel chromatography (petroleum ether / ethyl acetate = 0% to 6%) to obtain the target compound (compound 5e, 3.671 g, yield 90.3%) as a yellow oil. LCMS [M+1] + = 211.1.
[0056] Step 4: Preparation of compound 5f (methyl 2-(5-aminopyridin-2-yl)propionate) Add the appropriate palladium carbon to a solution of compound 5e (3.67 g, 17.460 mmol) in methanol (120 mL) at room temperature, purify with hydrogen several times, and then stir at room temperature for 2 hours. After the reaction is complete, filter the mixture, concentrate the filtrate under reduced pressure, and purify the residue by silica gel chromatography (petroleum ether / ethyl acetate = 0% to 50%) to obtain the target compound (compound 5f, 2.6025 g, yield 82.7%) as a yellow oil. LCMS [M+1] + = 181.
[0057] Step 5: Preparation of compound 5g (2-(5-aminopyridin-2-yl)propan-1-ol) In a 100mL three-neck flask, replace the air in the bottle with nitrogen, add lithium aluminum hydride (1.8g, 47.26mmol) in an ice bath, dropwise add tetrahydrofuran (180mL), and add a solution of compound 5f (1.31g, 7.27mmol) in tetrahydrofuran (20mL). Warm the reaction to room temperature and stir for 2 hours. After the reaction is complete, cool the reaction solution in an ice bath and dropwise add 1.8mL of water, 1.8mL of 15% aqueous sodium hydroxide solution, and 5.4mL of water in that order. Filter the mixture to obtain the filtrate, and wash the filter cake with ethyl acetate. Dry the filtrate over anhydrous sodium sulfate, filter, and concentrate to obtain the target compound (compound 5g, 1.2g, yield 95%) as a yellow oil. LCMS [M+1] + = 153.
[0058] Step 6: Preparation of compound 5 ((1S)-2,2-difluoro-N-(4-(2-((6-(1-(1-hydroxypropan-2-yl)pyridin-3-yl)amino))pyrimidin-4-yl)phenyl)cyclopropane-1-carboxamide) To a mixture of compound 389h (100 mg, 0.323 mmol), compound 389g (98 mg, 0.646 mmol), palladium acetate (7.3 mg, 0.032 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthracene (37.4 mg, 0.065 mmol), and cesium carbonate (316 mg, 0.969 mmol), dioxane (25 mL) was added, and the mixture was purged with argon several times. The mixture was then heated to 100° C. and stirred for 1 hour. After the reaction was completed, water (30 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic layers were combined, washed with water (60 mL) and saturated saline (60 mL), dried over sodium sulfate, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC (formic acid) to obtain the target compound TDM-180989 (compound 5, 30.3 mg, yield 18.4%) as a pale yellow solid. LCMS[M+H] + = 426.1. 1 H NMR (400 MHz, DMSO) δ 10.70(s, 1H), 9.71(s, 1H), 8.86(d, J = 2.5 Hz, 1H), 8.52(d, J = 5.3 Hz, 1H), 8.20 - 8.10(m, 3H), 7.77(d, J = 8.8 Hz, 2H), 7.39(d, J = 5.3 Hz, 1H), 7.22(d, J = 8.5 Hz, 1H), 4.60(s, 1H), 3.64(dd, J = 10.3, 6.6 Hz, 1H), 3.50(dd, J = 10.3, 7.0 Hz, 1H), 2.98 - 2.81(m, 2H), 2.13 - 1.94(m, 2H), 1.20(d, J = 10.3, 7.0 Hz, 1H) J = 7.0Hz, 3H).
[0059] <Example 6: General synthesis method of compound 6 (TDM-180971)> [ka] Step 1: Preparation of compound 6c (5-(2-chloropyrimidin-4-yl)pyridin-2-amine) Compound 6a (1.5 g, 10 mmol), compound 6b (2.21 g, 1.01 mmol), tetrakis(triphenylphosphine)palladium (1.16 g, 1 mmol), potassium carbonate (2.76 g, 20 mmol), 1,4-dioxane (60 mL), and water (60 mL) were added to a 250 mL three-neck flask, and the reaction solution was purged with nitrogen several times, heated to 80° C., and stirred for 45 minutes. + = 227, the completion of the reaction was detected. Work-up: The reaction solution was concentrated to dryness, and the obtained crude product was passed through a column [eluent: (EA / PE) = 0-70%] to obtain the target compound (compound 6c, 1.47 g, yield 71.36%) as a yellow solid. LCMS [M+1] + = 207.
[0060] Step 2: Preparation of compound 6e ((S)-N-(5-(2-chloropyrimidin-4-yl)pyridin-2-yl)-2,2-difluorocyclopropane-1-carboxamide) Compound 6d (910 mg, 7.47 mmol) and phosphorus oxychloride (1.64 g, 10.67 mmol) were added to a solution of compound 6c (1.47 g, 7.11 mmol) in anhydrous pyridine (50 ml). The reaction was stirred at room temperature for 1 hour and analyzed by LCMS [M+H + = 311, the completion of the reaction is detected. Work-up: The reaction solution is concentrated to dryness, the residue is extracted three times with water and ethyl acetate (3 × 100 mL), the organic phases are combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, concentrated, dried, and the obtained crude product is passed through a column [eluent: (EA / PE) = 0 ~ 30%], and the crude product is recrystallized again to obtain the target compound (compound 6e, 1.73 g, yield 78.6%) as a yellow solid. LCMS [M+H] + = 311.
[0061] Step 3: Preparation of compound 6 ((S)-4-((4-(6-(2,2-difluorocyclopropane-1-carboxamido)pyridin-3-yl)pyrimidin-2-yl)amino)-N-ethylbenzamide) Compound 6f (105.7 mg, 0.64 mmol) and p-toluenesulfonic acid monohydrate (122.5 mg, 0.64 mmol) were added to a solution of compound 6e (100 mg, 0.32 mmol) in n-butanol (10 ml). The reaction was heated to 110° C. and stirred for 2 hours. LCMS [M+H] + = 439, the reaction is complete. Workup: The reaction solution is concentrated to dryness, and the target compound (Compound 6, 12.3 mg, yield 8.7%) is obtained as a yellow solid by preparation. LCMS[M+H] + = 439.2. 1 H NMR (400MHz, DMSO)δ 11.30(s, 1H), 9.99(s, 1H), 9.25 - 9.06(m, 1H), 8.62(d, J = 5.2 Hz, 1H), 8.57(dd, J=8.8, 2.4Hz, 1H), 8.34 - 8.17(m, 2H), 7.90(d, J=8.9Hz, 2H), 7.82(d, J=8.9Hz, 2H), 7.53(d, J=5.2 Hz, 1H), 3.28(dt, J = 12.7, 6.4 Hz, 2H), 3.04(dd, J = 8.8, 5.7 Hz, 1H), 2.12-1.98(m, 2H), 1.13(t, J = 7.2 Hz, 3H).
[0062] <Example 7: General synthesis method of compound 7 (TDM-180979)> [ka] Step 1: Preparation of compound 7 ((S)-5-((4-(6-(2,2-difluorocyclopropane-1-carboxamido)pyridin-3-yl)pyrimidin-2-yl)amino)-N,3-dimethylpyridineamide) Compound 7b (106.3 mg, 0.64 mmol), palladium acetate (3.6 mg, 0.02 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthracene (18.6 mg, 0.03 mmol) and cesium carbonate (314.7 mg, 0.97 mmol) were added to a solution of compound 7a (100 mg, 0.32 mmol) in dioxane (25 ml). The reaction mixture was purged with argon several times, heated to 100 °C and stirred for 2 hours. LCMS [M + H] + The completion of the reaction is detected at 440° C. Work-up: The reaction solution is concentrated to dryness, and the residue is slurried with methanol to prepare a crude product to obtain the target compound (Compound 7, 6.4 mg, 3.2% yield) as a yellow solid. LCMS[M+1] + = 440.0. 1 H NMR (400MHz, DMSO) δ 11.34(s, 1H), 10.15(s, 1H), 9.17(d, J = 2.0 Hz, 1H), 8.87(d, J = 2.2 Hz, 1H), 8.65(d, J = 5.2 Hz, 1H), 8.56(dd, J = 8.8, 2.4 Hz, 1H), 8.50 (d, J = 4.8 Hz, 1H), 8.30 - 8.18 (m, 2H), 7.58 (d, J = 5.3Hz, 1H), 3.04 (dd, J = 8.9, 3.5Hz, 1H), 2.77 (d, J = 4.8Hz, 3H), 2.61(s, 3H), 2.05(dt, J = 10.7, 5.2Hz, 2H).
[0063] <Example 8: General synthesis method of compound 8 (TDM-180980)> [ka] Step 1: Preparation of compound 8 ((S)-5-((4-(6-(2,2-difluorocyclopropane-1-carboxamido)pyridin-3-yl)pyrimidin-2-yl)amino)-3-methylpyridinamide) Prepared in a similar manner to give compound 8 (2.3 mg, yellow solid, 1.2% yield). 1H NMR (400MHz, DMSO)δ 11.35(s, 1H), 10.16(s, 1H), 9.18(d, J = 2.0 Hz, 1H), 8.84(d, J = 2.2 Hz, 1H), 8.66(d, J = 5.2 Hz, 1H), 8.56(dd, J = 8.8, 2.4 Hz, 1H), 8.25(dd, J = 8.2, 5.5 Hz, 2H), 7.90(s, 1H), 7.58(d, J = 5.3 Hz, 1H), 7.25(s, 1H), 3.13 - 2.94(m, 1H), 2.61(s, 3H), 2.06(d, J = 9.6 Hz, 2H). LCMS[M+H] + = 426.1.
[0064] <Example 9: General synthesis method of compound 9 (TDM-180984)> [ka] Step 1: Preparation of compound 9 ((S)-4-((4-(6-(2,2-difluorocyclopropane-1-carboxamido)pyridin-3-yl)pyrimidin-2-yl)amino)-N-ethyl-2-methylbenzamide) Prepare in a similar manner to give compound 9 (26.6 mg, yellow solid, 13.04% yield). 1 H NMR (400MHz, DMSO)δ 11.33(s, 1H), 9.80(s, 1H), 9.17(d, J = 1.8 Hz, 1H), 8.68 - 8.49(m, 2H), 8.22(d, J = 8.7Hz, 1H), 8.09(t, J = 5.6Hz, 1H), 7.80 - 7.61(m, 2H), 7.50(d, J = 5.2Hz, 1H), 7.32(d, J = 8.4Hz, 1H), 3.28 - 3.19(m, 2H), 3.04(dt, J = 13.5, 9.8 Hz, 1H), 2.37(s, 3H), 2.12 - 2.00(m, 2H), 1.11(t, J = 7.2 Hz, 3H). LCMS[M+H] + = 453.2.
[0065] <Example 10: General synthesis method of compound 10 (TDM-180987)> [ka] Step 1: Preparation of compound 10 ((1S)-2,2-difluoro-N-(5-(2-((6-(1-(hydroxypropyl-2-yl)pyridyl-3-yl)amino))pyrimidinyl-4-yl)pyridinyl-2-ylcyclopropane-1-carboxamide) Prepared in a similar manner to give compound 10 (79 mg, off-white solid, 27.8% yield). 1 H NMR (400 MHz, DMSO) δ 11.30(s, 1H), 9.79(s, 1H), 9.13(d, J = 2.1 Hz, 1H), 8.84(d, J = 2.5 Hz, 1H), 8.65 - 8.46(m, 2H), 8.30 - 8.07(m, 2H), 7.48(d, J = 5.2 Hz, 1H), 7.22(d, J = 8.5 Hz, 1H), 4.59(t, J = 5.3 Hz, 1H), 3.71 - 3.43(m, 2H), 3.04(dt, J = 13.5, 9.9 Hz, 1H), 2.91(dt, J = 14.0, 7.0 Hz, 1H), 2.13 - 1.95(m, 2H), 1.20(d, J = 6.9 Hz, 3H). LCMS[M+H] + = 427.1.
[0066] Test Example 1. Enzyme Activity Inhibition Assay of Small Molecule Inhibitors of JAK Kinases Experimental Program 1. Preparation of Reagents Kinase reaction buffer: Prepare kinase reaction buffer, components are as follows: 50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 2 mM DTT, 0.01% Tween20.
[0067] 1X Assay Buffer: Prepare assay buffer by diluting 10X assay buffer to 1X with deionized water 9:1.
[0068] 4X Kinase Solution: Dilute JAK kinases to a final concentration of 4X (JAK1: 80 nM, JAK2 / JAK3 / Tyk2: 4 nM) in kinase reaction buffer.
[0069] 4X Substrate Solution: Dilute ULight™-JAK (Tyr1023) substrate to 200 nM (final concentration: 50 nM) in kinase reaction buffer.
[0070] 4X ATP solution: Dilute ATP to a final concentration of 4X (JAK1: 160 μM, JAK2 / JAK3 / Tyk2: 40 μM) in kinase reaction buffer.
[0071] 4X test compound solution: Dissolve test compounds in DMSO to a 10 mM stock solution and dilute in a 3-fold gradient to the required concentration. Ten concentration points are set for each compound, with the final test compound concentration range being 10 μM-0.5 nM.
[0072] 4X Enzyme Reaction Stop Solution: Dissolve EDTA to 40 mM (EDTA final concentration: 10 mM) in 1X Assay Buffer.
[0073] 4X Assay Antibody Solution: Dilute Eu-labeled assay antibody (anti-phosphorylated tyrosine (PT66)) to 8 nM (final concentration of antibody: 2 nM) in 1X Assay Buffer.
[0074] 2. Experimental Process 2.5μL of 4X kinase solution and 2.5μL of diluted 4X test compound solution of different concentrations are added to a 384 microwell plate in sequence, with two replicate wells for each concentration, and a blank control group and a negative control group (DMSO group) for the enzyme solution are set up at the same time. The 384-well plate is shaken to mix the enzyme and compound, centrifuged at 1000rpm for 1 minute, and incubated at room temperature for 60 minutes. 2.5μL of 4X substrate solution is added to the 384-well plate, and centrifuged at 1000rpm for 1 minute. 2.5μL of 4X ATP solution is added to the 384-well plate, and centrifuged at 1000rpm for 1 minute to start the enzyme reaction. JAK1 is reacted at room temperature for 2 hours, and JAK2 / JAK3 / Tyk2 is reacted at room temperature for 1 hour. The final concentrations of each component of the JAK1 reaction are JAK1: 20 nM, substrate: 50 nM, ATP: 40 uM, and the final concentration range of the test compound is 10 μM-0.5 nM. The final concentrations of each component of the JAK2 / JAK3 / Tyk2 reaction are JAK2: 1 nM, substrate: 50 nM, ATP: 10 μM, and the final concentration range of the test compound is 10 μM-0.5 nM. After the enzyme reaction is complete, add 5 μL of 4X enzyme reaction stop solution to each well of the 384-well plate, centrifuge at 1000 rpm for 1 minute, and incubate at room temperature for 5 minutes. Add 5 μL of 4X assay antibody solution to each well of the 384-well plate (final concentration of assay antibody is 2 nM), centrifuge at 1000 rpm for 1 minute, and incubate at room temperature for 1 hour. After antibody incubation, measure the signal value of each well with an Envision plate reader.
[0075] 3. Data Analysis The inhibition rate corresponding to each concentration was calculated by setting the blank control group of the enzyme solution as 100% inhibition rate and the negative control group (DMSO group) as 0% inhibition rate. A nonlinear regression analysis was performed on the logarithm of the concentration of the assay compound and the corresponding percent inhibition rate using GraphPad Prism software to calculate the half inhibitory concentration (IC 50 The experimental results obtained with the compounds of Examples 1 to 10 are shown in Table 1 below.
[0076] [Table 1]
[0077] As can be seen from the results in Table 1 above, the compounds of the present application have excellent enzyme activity data, and the half-inhibitory concentrations measured for the specific compounds are low, especially for Tyk2, JAK1 and JAK2, they are basically less than 0.03 μM, especially for compounds TDM-180972, TDM-180974, TDM-180977, TDM-180981, TDM-180971 and TDM-180984, the half-inhibitory concentrations are all less than 0.01 μM. Therefore, the above experiments prove that the small molecule compounds of the present application are compounds with strong targeting to the JAK family and excellent enzyme activity, and can be used as JAK1 / Tyk2 dual inhibitors and Tyk2 specific inhibitors.
[0078] Although the preferred embodiments of the present invention have been described in detail above, the present invention is not limited to the specific contents of the above embodiments. Various simple modifications can be made to the technical solutions of the present invention within the scope of the technical idea of the present invention, and all such simple modifications fall within the protection scope of the present invention.
[0079] It should be further noted that the various specific technical features described in the above specific embodiments may be combined in any suitable manner unless contradictory, and in order to avoid unnecessary duplication, the present invention does not separately describe the various possible combination forms.
[0080] Furthermore, any combination between the various different embodiments according to the present invention is possible, and unless contrary to the spirit of the present invention, such combinations should also be considered as the disclosure of the present invention.
Claims
1. A small molecule compound, characterized in that it is a compound represented by the following formula I, or a stereoisomer, geometric isomer, tautomer, hydrate, solvate, or pharma- ceutically acceptable salt thereof: 【Chemistry 1】 Where: R 1 ~R 4 are each independently selected from C or N; R has a structure represented by Formula II or Formula III shown below: 【Chemistry 2】 Where: R 5 is selected from C or N; R 6 is selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 7 is selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 8 is selected from C or N; R 9 is selected from hydrogen, halogen, alkyl, amino, amido, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 10 is selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
2. R 1 ~R 4 The small molecule compound of claim 1, wherein up to two of are N.
3. R 6 and R 7 The small molecule compound of claim 1 , wherein each is independently selected from hydrogen, alkyl, or cycloalkyl.
4. R 9 and R 10 The small molecule compound of claim 1 , wherein each is independently selected from hydrogen, alkyl, or cycloalkyl.
5. 5. The small molecule compound of claim 3 or 4, characterized in that the alkyl group is methyl, ethyl, propyl or isopropyl, and the cycloalkyl group is cyclopropyl, cyclobutyl or cyclopropylmethyl.
6. A drug comprising the small molecule compound of any one of claims 1 to 5 for inhibiting a JAK kinase.
7. A drug for preventing or treating JAK-associated autoimmune diseases and immune-associated inflammatory skin diseases, the pathogenesis of both diseases being related to dysregulation of JAK signaling, comprising a small molecule compound according to any one of claims 1 to 5.
8. 8. The method of claim 7, wherein the autoimmune disease is selected from at least one of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, dermatomyositis, multiple sclerosis, type I diabetes, Sjogren's syndrome, and vasculitis.
9. 8. The method of claim 7, wherein the immune-related inflammatory skin disease is selected from at least one of atopic dermatitis, eczema, alopecia areata, psoriasis, vitiligo, lichen planus, lichen nitidus, lichen sclerosus, panniculitis, acne, and hidradenitis suppurativa.
Citation Information
Patent Citations
Small molecule compound
CN110627775A
Use of compositions as jak inhibitors and other protein kinase inhibitors
JP2006512314A
4-aryl-2-aminopyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 regulators and their usage
JP2009525337A
Phenylaminopyrimidine compounds and their uses
JP2010520892A
Substitutive heterocycles as JANUS kinase inhibitors
JP2011503194A
